



BRW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/823,211
	Filing Date	April 13, 2004
	First Named Inventor	Haag et al.
	Art Unit	1614
	Examiner Name	V. Balasubramanian
Total Number of Pages in This Submission	Attorney Docket Number	20945 US1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Brian C. Remy	
Signature		
Date	November 5, 2004	

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Brian C. Remy
Signature	
Date	November 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Rainer Haag et al.

Group: 1624

Serial No. 10/823,211, filed April 13, 2004

Examiner: V. Balasubramanian

For: **N-MONOACYLATED DERIVATIVES OF O-PHENYLENEDIAMINES,
THEIR ANALOGS AND THEIR USE AS PHARMACEUTICAL AGENTS**

RESPONSE TO RESTRICTION REQUIREMENT

Nutley, New Jersey 07110
November 5, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully request consideration of the following remarks in response to the Restriction Requirement issued October 5, 2004 in connection with the above-identified application. This response is due November 5, 2004.

Claims 1 to 30 are pending. The claims have been divided into three groups as set forth below:

- I. Claims 1 to 30, drawn to the compounds, compositions, methods of making and methods of using the compounds of formula I, wherein X^1 and X^2 are both nitrogen, classified in class 544, subclasses 326, 328, and class 514, subclass 256.
- II. Claims 1 to 30, drawn to the compounds, compositions, methods of making and methods of using the compounds of formula I, wherein one of X^1 or X^2

is nitrogen and the other carbon, classified in class 546, subclasses 268.01, 307, and class 514, subclass 352.

- III. Claims 1 to 30, drawn to the compounds, compositions, methods of making and methods of using the compounds of formula I, wherein X¹ and X² are both carbon, classified in class 564, subclasses 123, 244 and class 514, subclass 615.

The Office Action indicates that restriction is proper because the compounds delineated in each of the three groups are structurally dissimilar compounds that lack a common core (e.g. pyrimidine versus pyridine versus benzene cores). Consequently, according to the Examiner, the groups have different classifications, require separate prior art searches, can be made and used independently, and a reference anticipating one group would not render the other groups obvious.

Applicants hereby provisionally elect with traverse Group III relating to the benzene (or phenyl) compounds of claims 1-30 for prosecution on the merits. Applicants also provisionally elect with traverse the species benzofuran-2-carboxylic acid (2-amino-phenyl) amide of claim 3 if no generic claim is held allowable.

In addition, it is respectfully noted that the Applicants elected Group III in the parent application but point out that the Examiner withdrew claims 12-16 as nonelected even though claims 12-13 and the majority of claim 14 were drawn to the benzene core of Group III (*i.e.*, the 4,5-dichloro-**phenyl** compounds). Accordingly, it is respectfully requested that in this application the Examiner not withdraw claims 12-13 or that portion of claim 14 drawn to Group III if the restriction requirement is maintained.

The restriction requirement is traversed because Applicants believe that no serious burden exists to search and examine the invention as a whole (MPEP § 803). Restriction between structurally diverse compounds is permitted only when there is a serious burden on the Patent Office to examine the invention as a whole. If the search and examination of the


Serial No. 10/823,211
Filed: April 13, 2004

entire application can be made without serious burden, the Examiner must examine it on the merits. Applicants note that all three of the groups delineated in the Office Action are classified in Class 514. In addition, because all of the compounds are useful for the same purpose, issues related to search and examination would be the same for all of the claimed compounds. Accordingly, the Applicants respectfully request reconsideration and withdrawal of the restriction requirement and examination of the application in its entirety.

The foregoing is submitted as a full and complete response to the restriction requirement. Early and favorable consideration of the entire application is respectfully requested. No additional fees are believed due with the filing of this response; however, the Director is hereby authorized to charge any additional fees, or credit any overpayment, to Deposit Account No. 08-2525.

If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or if there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (973) 235-6516 is respectfully requested.

Respectfully submitted,



Brian C. Remy
Attorney for Applicant(s)
(Reg. No. 48,176)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6516
Telefax: (973) 235-2363

147772